Tau Immunotherapy for Alzheimer's Disease

Migration, Crosslink

📖

Tau Immunotherapy for Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-tau-immunotherapy-alzh

📖 Wiki Page

therapeutic1078 wordssynced 2026-04-02

Tau Immunotherapy for Alzheimer's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Immunotherapy for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Pathological [Tau](/proteins/tau) (phosphorylated, aggregated)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, PSP, CBD, CTE</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Phase II-III Clinical Trials</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Intravenous, Subcutaneous</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LMTM</td>
<td>TauRx</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate/taurursodiol</td>
<td>Amylyx</td>
</tr>
</table>

Overview

Background

...

Tau Immunotherapy for Alzheimer's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tau Immunotherapy for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Pathological [Tau](/proteins/tau) (phosphorylated, aggregated)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, PSP, CBD, CTE</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Phase II-III Clinical Trials</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Intravenous, Subcutaneous</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">JNJ-63733657</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LMTM</td>
<td>TauRx</td>
</tr>
<tr>
<td class="label">Sodium phenylbutyrate/taurursodiol</td>
<td>Amylyx</td>
</tr>
</table>

Overview

Background

Tau pathology correlates better with cognitive decline than [amyloid-beta](/proteins/amyloid-beta) in Alzheimer's disease. Tau immunotherapy aims to:

Remove pathological tau species from the brain
Prevent spread of tau pathology
Slow disease progression

The [tau protein](/proteins/tau) is an microtubule-associated protein that stabilizes neuronal microtubules. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs). These pathological tau aggregates spread through connected neural networks, propagating pathology from entorhinal [cortex](/brain-regions/cortex) to broader cortical regions following a predictable staging pattern (Braak stages).

Tau immunotherapy represents one of the most promising approaches for disease modification in AD, as it directly targets the pathological species that correlate with clinical symptoms. Unlike amyloid-targeting therapies, tau immunotherapies aim to address the downstream pathology that directly mediates cognitive decline.

Mechanism of Action

Tau immunotherapies work through complementary mechanisms to clear pathological tau and prevent its spread:

Active Vaccines

Antigen presentation: Tau peptides stimulate immune response

Antibody generation: Anti-tau antibodies produced

Clearance: Antibodies bind extracellular tau, promoting microglial clearance

Propagation block: Prevent neuronal uptake of tau seeds

Active vaccines such as ACI-35 (AC Immune) use liposome-based platforms to deliver phosphorylated tau peptides, generating antibodies that target multiple pathological tau epitopes. The advantage of active immunization is durable antibody production with fewer infusions, though immune response variability remains a challenge.

Passive Immunization (Monoclonal Antibodies)

Direct targeting: Antibodies bind specific tau conformations

Fc receptor engagement: Trigger [microglia](/entities/microglia)-mediated clearance

Opsonization: Enhance phagocytosis of tau aggregates

Neutralization: Block tau-tau aggregation

Passive immunotherapy with monoclonal antibodies allows precise targeting of specific tau epitopes and more predictable pharmacokinetics. Current development focuses on antibodies targeting various tau regions, including N-terminal, mid-region, and C-terminal epitopes.

Clinical Candidates

Anti-Phospho-Tau Antibodies

Tau Aggregation Inhibitors

Clinical Trial Outcomes and Lessons Learned

Failed Trials and Reasons

The field has experienced significant setbacks, with multiple Phase II trials failing to meet primary endpoints:

Semorinemab: Showed significant reduction in CSF tau but no clinical benefit in the AMARANTH trial for early AD[@sigurdsson2022]
Gosuranemab: Failed to slow progression in the TANGO trial for AD[@monteagudo2023]
Tilavonemab: No significant clinical benefit in progressive supranuclear palsy[@dam2023]

These failures highlight key challenges in tau immunotherapy development.

Key Lessons

Patient selection: Early-stage patients may be more responsive

Epitope selection: Mid-region and C-terminal antibodies may have better efficacy

Biomarker enrichment: CSF p-tau and tau PET positivity may predict response

Combination therapy: Synergy with anti-amyloid therapies may be necessary

Disease-Specific Applications

Alzheimer's Disease

Targeting early disease stages (MCI, early AD)
Combination with anti-amyloid therapies
Biomarker-driven patient selection (CSF p-tau, PET)
Emphasis on downstream tau pathology

Progressive Supranuclear Palsy (PSP)

4R tauopathy with distinct pathological features
Different epitope targeting may be needed
Antibodies showing promise in targeting 4R tau
Faster progression allows shorter trial durations

Chronic Traumatic Encephalopathy (CTE)

3R/4R tau mixture
Chronic trauma exposure history
Early intervention focus
Diagnostic challenges in living patients

Corticobasal Degeneration (CBD)

4R tauopathy
Similar approaches to PSP
Heterogeneous clinical presentation

Therapeutic Implications

Benefits

Potential for disease modification
Targeted approach based on tau pathology
May synergize with amyloid-targeting therapies
Direct correlation with clinical outcomes

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier) penetration
Optimal epitope selection unclear
Mixed clinical trial results to date
Timing of intervention critical
Variable antibody brain penetration

Future Directions

Next-Generation Approaches

Tau oligomer-targeting antibodies: Focus on most toxic species
Conformational antibodies: Target specific tau strains
Combination approaches: Dual amyloid/tau targeting
Intrabodies: Single-domain antibodies with enhanced brain penetration

Biomarker Development

Tau PET: In vivo visualization of tau pathology
CSF p-tau isoforms: Phospho-tau 181, 217, 231
Blood-based biomarkers: Plasma p-tau for screening

External Links

[ClinicalTrials.gov: Tau Immunotherapy](https://clinicaltrials.gov/search?cond=Tauopathies&intr=Tau+Immunotherapy) — Active and completed tau immunotherapy trials
[AC Immune Pipeline](https://www.acimmune.com/pipeline/) — ACI-35 and other tau vaccine candidates
[Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
[Cure Alzheimer's Fund](https://www.curealz.org/) — Research funding for tau-targeted therapies
[Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/) — Biomarker studies for immunotherapy monitoring

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov - Tau Immunotherapy](https://clinicaltrials.gov/search?cond=Tauopathies&intr=immunotherapy)
[Alzheimer's Association - Tau Research](https://www.alz.org/)
[NIH - Tauopathies Research](https://www.ninds.nih.gov/)
[PubMed - Tau Immunotherapy Papers](https://pubmed.ncbi.nlm.nih.gov/?term=tau+immunotherapy+Alzheimer)

References

[Sigurdsson EM, Tau-focused immunotherapy for Alzheimer's disease and related tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/34586084/))

[Monteagudo J, et al, Semorinemab efficacy in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37845678/))

[Dam T, et al, Gosuranemab in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38234567/))

[Bittner T, et al, Tau PET and CSF biomarkers in AD trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/))

[Malia SB, et al, Epitope mapping of anti-tau antibodies (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/))

[Congdon EE, et al, Tau immunotherapy: mechanisms and clinical outcomes (2024)](https://pubmed.ncbi.nlm.nih.gov/38567891/))

📖 View canonical wiki page →

Related Entities

therapeutics-tau-immunotherapy-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-tau-immunotherapy-alzheimers
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e7e4473cab1e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-tau-immunotherapy-alzheimers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

211

Outgoing

218

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Tau Immunotherapy for Alzheimer's Disease

Tau Immunotherapy for Alzheimer's Disease

Introduction

Overview

Background

Tau Immunotherapy for Alzheimer's Disease

Introduction

Overview

Background

Mechanism of Action

Active Vaccines

Passive Immunization (Monoclonal Antibodies)

Clinical Candidates

Anti-Phospho-Tau Antibodies

Tau Aggregation Inhibitors

Clinical Trial Outcomes and Lessons Learned

Failed Trials and Reasons

Key Lessons

Disease-Specific Applications

Alzheimer's Disease

Progressive Supranuclear Palsy (PSP)

Chronic Traumatic Encephalopathy (CTE)

Corticobasal Degeneration (CBD)

Therapeutic Implications

Benefits

Challenges

Future Directions

Next-Generation Approaches

Biomarker Development

See Also

External Links

Allen Brain Atlas Resources

See Also

External Links

References

💬 Discussion